Compare Incyte Corporation (INCY) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs KeyCorp — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while KeyCorp trades at $22.7 (market cap $24.32B). The key difference: Incyte Corporation and KeyCorp are close in size by market cap, and KeyCorp pays a 3.61% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | KEY | |
|---|---|---|
Market Cap | $24.54B | $24.32B |
Sector | Health | Financials |
52-Week High | $129.93 | $23.99 |
52-Week Low | $81.61 | $16.78 |
Enterprise Value | $20.04B | — |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
KeyCorp (KEY) trades at $22.94, up 1.15% today, with a bullish analyst consensus and consistent earnings beats. The stock shows a P/E of 13.27 and net income margin of 26.72%, supported by strong Q2 2026 results. Recent acquisition of Clearwater UK expands its investment banking footprint, while technical indicators signal a bearish trend despite neutral oscillators.
Outlook remains positive with a $29.41 price target, driven by net interest income growth and fee-based expansion. Risks include economic uncertainty impacting loan demand and competitive pressures. The dividend yield of approximately 3.6% adds income appeal, but investors should monitor margin sustainability and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
